Advertisement

Heart and Vessels

, Volume 31, Issue 6, pp 855–862 | Cite as

Lower 1,5-anhydroglucitol is associated with adverse clinical events after percutaneous coronary intervention

  • Takayuki Fujiwara
  • Masashi Yoshida
  • Naoyuki Akashi
  • Hodaka Yamada
  • Takunori Tsukui
  • Tomohiro Nakamura
  • Kenichi Sakakura
  • Hiroshi Wada
  • Kenshiro Arao
  • Takuji Katayama
  • Tomio Umemoto
  • Hiroshi Funayama
  • Yoshitaka Sugawara
  • Takeshi Mitsuhashi
  • Masafumi Kakei
  • Shin-ichi MomomuraEmail author
  • Junya Ako
Original Article

Abstract

Diabetes mellitus and impaired glucose tolerance are well-known risk factors for coronary artery disease (CAD) and adverse clinical events after percutaneous coronary intervention (PCI). Postprandial hyperglycemia is an important risk factor for CAD and serum 1,5-anhydroglucitol (1,5-AG) reflects postprandial hyperglycemia more robustly than hemoglobin (Hb)A1c. We aimed to clarify the relationship between serum 1,5-AG level and adverse clinical events after PCI. We enrolled 141 patients after PCI with follow-up coronary angiography. We evaluated associations between glycemic biomarkers including HbA1c and 1,5-AG and cardiovascular events during follow-up. Median serum 1,5-AG level was significantly lower in patients with any coronary revascularization and target lesion revascularization (TLR) [13.4 µg/ml (first quartile, third quartile 9.80, 18.3) vs. 18.7 (12.8, 24.2), p = 0.005; 13.4 µg/ml (10.2, 16.4) vs. 18.7 (12.9, 24.2), p = 0.001, respectively]. Multivariate logistic analysis showed lower 1,5-AG was independently associated with any coronary revascularization and TLR (odds ratio 0.93, 95 % confidence interval 0.86–0.99, p = 0.04; 0.90, 0.81–0.99, p = 0.044, respectively), whereas higher HbA1c was not. Postprandial hyperglycemia and lower 1,5-AG are important risk factors for adverse clinical events after PCI.

Keywords

Postprandial hyperglycemia Diabetes mellitus Percutaneous coronary intervention Target lesion revascularization 

Notes

Acknowledgments

We wish to thank the staff at our hospital for their assistance with sample collection, and the patients for their participation in the study.

Conflict of interest

None.

References

  1. 1.
    Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M (1998) Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339(4):229–234CrossRefPubMedGoogle Scholar
  2. 2.
    Cassese S, Byrne RA, Tada T, Pinieck S, Joner M, Ibrahim T, King LA, Fusaro M, Laugwitz KL, Kastrati A (2014) Incidence and predictors of restenosis after coronary stenting in 10,004 patients with surveillance angiography. Heart 100(2):153–159CrossRefPubMedGoogle Scholar
  3. 3.
    UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352(9131):837–853Google Scholar
  4. 4.
    Nakanishi S, Yamada M, Hattori N, Suzuki G (2005) Relationship between HbA(1)c and mortality in a Japanese population. Diabetologia 48(2):230–234CrossRefPubMedGoogle Scholar
  5. 5.
    Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B (2005) Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353(25):2643–2653CrossRefPubMedGoogle Scholar
  6. 6.
    Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR (2000) Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321(7258):405–412CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    UK Prospective Diabetes Study (UKPDS) Group (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352(9131):854–865Google Scholar
  8. 8.
    Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M (2003) Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 290(4):486–494CrossRefPubMedGoogle Scholar
  9. 9.
    Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefebvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Koranyi L, Laakso M, Mokan M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366(9493):1279–1289CrossRefPubMedGoogle Scholar
  10. 10.
    Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M (2004) Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J 25(1):10–16CrossRefPubMedGoogle Scholar
  11. 11.
    The DECODE study group (1999) Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European diabetes epidemiology group. Diabetes epidemiology: collaborative analysis of diagnostic criteria in Europe. Lancet 354(9179):617–621CrossRefGoogle Scholar
  12. 12.
    Donahue RP, Abbott RD, Reed DM, Yano K (1987) Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry Honolulu Heart Program. Diabetes 36(6):689–692CrossRefPubMedGoogle Scholar
  13. 13.
    Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A (1999) Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 22(6):920–924CrossRefPubMedGoogle Scholar
  14. 14.
    Dungan KM, Buse JB, Largay J, Kelly MM, Button EA, Kato S, Wittlin S (2006) 1,5-anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes. Diabetes Care 29(6):1214–1219CrossRefPubMedGoogle Scholar
  15. 15.
    Yamanouchi T, Moromizato H, Shinohara T, Minoda S, Miyashita H, Akaoka I (1992) Estimation of plasma glucose fluctuation with a combination test of hemoglobin A1c and 1,5-anhydroglucitol. Metabolism 41(8):862–867CrossRefPubMedGoogle Scholar
  16. 16.
    Fujiwara T, Yoshida M, Yamada H, Tsukui T, Nakamura T, Sakakura K, Wada H, Arao K, Katayama T, Funayama H, Sugawara Y, Mitsuhashi T, Kakei M, Momomura SI, Ako J (2014) Lower 1,5-anhydroglucitol is associated with denovo coronary artery disease in patients at high cardiovascular risk. Heart Vessels. doi: 10.1007/s00380-014-0502-y Google Scholar
  17. 17.
    Ikeda N, Hara H, Hiroi Y (2014) 1,5-Anhydro-d-glucitol predicts coronary artery disease prevalence and complexity. J Cardiol 64(4):297–301CrossRefPubMedGoogle Scholar
  18. 18.
    Ogihara T, Kikuchi K, Matsuoka H, Fujita T, Higaki J, Horiuchi M, Imai Y, Imaizumi T, Ito S, Iwao H, Kario K, Kawano Y, Kim-Mitsuyama S, Kimura G, Matsubara H, Matsuura H, Naruse M, Saito I, Shimada K, Shimamoto K, Suzuki H, Takishita S, Tanahashi N, Tsuchihashi T, Uchiyama M, Ueda S, Ueshima H, Umemura S, Ishimitsu T, Rakugi H (2009) The Japanese Society of hypertension guidelines for the management of hypertension (JSH 2009). Hypertens Res 32(1):3–107PubMedGoogle Scholar
  19. 19.
    Seino Y, Nanjo K, Tajima N, Kadowaki T, Kashiwagi A, Araki E, Ito C, Inagaki N, Iwamoto Y, Kasuga M, Hanafusa T, Haneda M, Ueki K (2010) Report of the committee on the classification and diagnostic criteria of diabetes mellitus. Diabetol Int 1(1):2–20CrossRefGoogle Scholar
  20. 20.
    Harris P, Conley M, Behar V, Rosat R (1979) The prognostic significance of the degree of coronary stenosis. Am J Cardiol 43(2):343Google Scholar
  21. 21.
    Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A (2009) Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53(6):982–992CrossRefPubMedGoogle Scholar
  22. 22.
    Lubsen J, Wagener G, Kirwan BA, de Brouwer S, Poole-Wilson PA (2005) Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension: the ACTION trial. J Hypertens 23(3):641–648CrossRefPubMedGoogle Scholar
  23. 23.
    Yui Y, Sumiyoshi T, Kodama K, Hirayama A, Nonogi H, Kanmatsuse K, Origasa H, Iimura O, Ishii M, Saruta T, Arakawa K, Hosoda S, Kawai C (2004) Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) randomized trial. Hypertens Res 27(3):181–191CrossRefPubMedGoogle Scholar
  24. 24.
    Mabuchi H, Kita T, Matsuzaki M, Matsuzawa Y, Nakaya N, Oikawa S, Saito Y, Sasaki J, Shimamoto K, Itakura H (2002) Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia and coronary heart disease: secondary prevention cohort study of the Japan Lipid Intervention Trial (J-LIT). Circ J 66(12):1096–1100CrossRefPubMedGoogle Scholar
  25. 25.
    Sakamoto T, Kojima S, Ogawa H, Shimomura H, Kimura K, Ogata Y, Sakaino N, Kitagawa A (2006) Effects of early statin treatment on symptomatic heart failure and ischemic events after acute myocardial infarction in Japanese. Am J Cardiol 97(8):1165–1171CrossRefPubMedGoogle Scholar
  26. 26.
    Selvin E, Coresh J, Golden SH, Brancati FL, Folsom AR, Steffes MW (2005) Glycemic control and coronary heart disease risk in persons with and without diabetes: the atherosclerosis risk in communities study. Arch Intern Med 165(16):1910–1916CrossRefPubMedGoogle Scholar
  27. 27.
    Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358(24):2545–2559CrossRefPubMedGoogle Scholar
  28. 28.
    Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I (2013) Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369(14):1317–1326CrossRefPubMedGoogle Scholar
  29. 29.
    White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Cushman WC, Zannad F (2013) Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 369(14):1327–1335CrossRefPubMedGoogle Scholar
  30. 30.
    Kastrati A, Dibra A, Mehilli J, Mayer S, Pinieck S, Pache J, Dirschinger J, Schomig A (2006) Predictive factors of restenosis after coronary implantation of sirolimus- or paclitaxel-eluting stents. Circulation 113(19):2293–2300CrossRefPubMedGoogle Scholar
  31. 31.
    Yamanouchi T, Akanuma Y, Toyota T, Kuzuya T, Kawai T, Kawazu S, Yoshioka S, Kanazawa Y, Ohta M, Baba S et al (1991) Comparison of 1,5-anhydroglucitol, HbA1c, and fructosamine for detection of diabetes mellitus. Diabetes 40(1):52–57CrossRefPubMedGoogle Scholar
  32. 32.
    Holman RR, Haffner SM, McMurray JJ, Bethel MA, Holzhauer B, Hua TA, Belenkov Y, Boolell M, Buse JB, Buckley BM, Chacra AR, Chiang FT, Charbonnel B, Chow CC, Davies MJ, Deedwania P, Diem P, Einhorn D, Fonseca V, Fulcher GR, Gaciong Z, Gaztambide S, Giles T, Horton E, Ilkova H, Jenssen T, Kahn SE, Krum H, Laakso M, Leiter LA, Levitt NS, Mareev V, Martinez F, Masson C, Mazzone T, Meaney E, Nesto R, Pan C, Prager R, Raptis SA, Rutten GE, Sandstroem H, Schaper F, Scheen A, Schmitz O, Sinay I, Soska V, Stender S, Tamas G, Tognoni G, Tuomilehto J, Villamil AS, Vozar J, Califf RM (2010) Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med 362(16):1463–1476CrossRefPubMedGoogle Scholar
  33. 33.
    Sawada T, Shiotani H, Terashita D, Nagasawa Y, Kim SS, Koide M, Yokoyama M (2014) Comparison of effects of alpha-Glucosidase inhibitors and glinide drugs on endothelial dysfunction in diabetic patients with coronary artery disease. Circ J 78(1):248–255CrossRefPubMedGoogle Scholar
  34. 34.
    Watanabe K, Suzuki T, Ouchi M, Suzuki K, Ohara M, Hashimoto M, Yamashita H, Okazaki M, Ishii K, Oba K (2013) Relationship between postprandial glucose level and carotid artery stiffness in patients without diabetes or cardiovascular disease. BMC Cardiovasc Disord 13:11CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Ouchi M, Oba K, Motoyama M, Tsunoda M, Yamashita H, Aoyama J, Saigusa T, Ishii K, Yano H, Hashimoto M, Sekimizu K, Suzuki T, Nakano H (2014) Postprandial glycemic control conditions in relation to urinary N-acetyl-beta-d-glucosaminidase in patients with type 2 diabetes mellitus without low glomerular filtration rate. Diabetes Technol Ther 16(1):41–47CrossRefPubMedGoogle Scholar
  36. 36.
    Hashiba M, Ono M, Hyogo H, Ikeda Y, Masuda K, Yoshioka R, Ishikawa Y, Nagata Y, Munekage K, Ochi T, Hirose A, Nozaki-Fujimura Y, Noguchi S, Okamoto N, Chayama K, Suganuma N, Saibara T (2013) Glycemic variability is an independent predictive factor for development of hepatic fibrosis in nonalcoholic fatty liver disease. PLoS ONE 8(11):e76161CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Japan 2015

Authors and Affiliations

  • Takayuki Fujiwara
    • 1
  • Masashi Yoshida
    • 2
  • Naoyuki Akashi
    • 1
  • Hodaka Yamada
    • 2
  • Takunori Tsukui
    • 1
  • Tomohiro Nakamura
    • 1
  • Kenichi Sakakura
    • 1
  • Hiroshi Wada
    • 1
  • Kenshiro Arao
    • 1
  • Takuji Katayama
    • 1
  • Tomio Umemoto
    • 1
  • Hiroshi Funayama
    • 1
  • Yoshitaka Sugawara
    • 1
  • Takeshi Mitsuhashi
    • 1
  • Masafumi Kakei
    • 2
  • Shin-ichi Momomura
    • 1
    Email author
  • Junya Ako
    • 3
  1. 1.Department of Cardiovascular Medicine, Saitama Medical CenterJichi Medical UniversitySaitamaJapan
  2. 2.Department of Endocrinology and Metabolism, Saitama Medical CenterJichi Medical UniversitySaitamaJapan
  3. 3.Department of Cardiovascular MedicineKitasato UniversitySagamiharaJapan

Personalised recommendations